Clinical features and outcome of SIL/TAL1-positive t-cell acute lymphoblastic leukemia in children and adolescents: A 10-year experience of the AIEOP group

Haematologica

Volumn 100, Issue 1, 2015, Pages e10-e13

  D’Angiò, Mariella ^a   Valsecchi, Maria G ^b   Testi, Anna M ^a   Conter, Valentino ^c   Nunes, Vittorio ^a   Parasole, Rosanna ^d   Colombini, Antonella ^c   Santoro, Nicola ^e   Varotto, Stefania ^f   Caniglia, Maurizio ^g   Silvestri, Daniela ^b,c   Consarino, Caterina ^h   Levati, Laura ^c   Magrin, Elisa ^f   Locatelli, Franco ^c,i   Basso, Giuseppe ^f   Foà, Robin ^a   Biondi, Andrea ^c   Cazzaniga, Gianni ^c  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b UNIVERSITY OF MILANO BICOCCA   (Italy)

^c SAN GERARDO HOSPITAL   (Italy)

^d Ospedale Pausilipon   (Italy)

^e UNIVERSITY OF BARI   (Italy)

^f UNIVERSITY OF PADOVA   (Italy)

^g Ospedale SM Della Misericordia   (Italy)

^h PUGLIESE CIACCIO HOSPITAL   (Italy)

ⁱ BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

Author keywords

Acute lymphoblastic leukemia; Children and adolescents; SIL TAL1

Indexed keywords

GENOMIC DNA; TRANSCRIPTION FACTOR TAL1; ANTINEOPLASTIC AGENT; BASIC HELIX LOOP HELIX TRANSCRIPTION FACTOR; ONCOPROTEIN; SIGNAL PEPTIDE; SIL-TAL1 FUSION PROTEIN, HUMAN; STIL PROTEIN, HUMAN; TAL1 PROTEIN, HUMAN; TUMOR MARKER;

ADOLESCENT; CANCER CHEMOTHERAPY; CANCER SPECIFIC SURVIVAL; CHILD; CLINICAL EVALUATION; CLINICAL FEATURE; FEMALE; FOLLOW UP; GENE MUTATION; GENETIC ANALYSIS; HUMAN; LETTER; LEUKOCYTE DIFFERENTIAL COUNT; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRESCHOOL CHILD; QUANTITATIVE ANALYSIS; RISK FACTOR; SCHOOL CHILD; T CELL LEUKEMIA; TREATMENT RESPONSE; CANCER STAGING; COHORT ANALYSIS; DRUG RESISTANCE; GENETICS; IMMUNOPHENOTYPING; INFANT; METABOLISM; MORTALITY; PATHOLOGY; POLYMERASE CHAIN REACTION; PRECURSOR T-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROGNOSIS; SURVIVAL RATE; TUMOR RECURRENCE;

ADOLESCENT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; BIOMARKERS, TUMOR; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; DRUG RESISTANCE, NEOPLASM; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOPHENOTYPING; INFANT; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; ONCOGENE PROTEINS, FUSION; PATIENT OUTCOME ASSESSMENT; POLYMERASE CHAIN REACTION; PRECURSOR T-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROGNOSIS; PROTO-ONCOGENE PROTEINS; SURVIVAL RATE;

EID: 84920178694     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2014.112151     Document Type: Letter

References (15)

1. Cavè H, Suciu S, Preudhomme C, Poppe B, Robert A, Uyttebroeck A, et al. Clinical significance of HOX11L2 expression linked to t(5;14)(q35;q32), of HOX11 expression, and SIL-TAL fusion in childhood T-Cell malignancies: results of EORTC studies 58881 and 58951. Blood. 2004;103(2):442-50.
2. Conter V, Aricò M, Basso G, Biondi A, Barisone E, Messina C, et al. Long-term results of the Italian Association of Pediatric Hematology and Oncology (AIEOP) Studies 82, 87, 88, 91 and 95 for childhood acute lymphoblastic leukemia. Leukemia. 2010;24(2):255-64.
3. Van Grotel M, Meijerink J, Beverloo HB, Langerak AW, Buys- Gladdines JG, Schneider P, et al. The outcome of molecular cytogenetic subgroups in pediatric T cell acute lymphoblastic leukemia; a retrospective study of patients treated according to DCOG or COALL protocols. Haematologica. 2006;91(9):1212-21.
4. Bassan R, Hoelzer D. Modern therapy of acute lymphoblastic leukemia. J Clin Oncol. 2011;29(5):534-43.
5. La Starza R, Lettieri A, Pierini V, Nofrini V, Gorello P, Songia S, et al. Linking genomic lesions with minimal residual disease improves prognostic stratification in children with T-cell acute lymphoblastic leukaemia. Leuk Res. 2013;37(8):928-35.
6. Bash RO, Hall S, Timmons CF, Crist WM, Smith RG, Baer R. Does activation of the TAL1 gene occur in a majority of patients with Tcell acute lymphoblastic leukemias? A pediatric oncology group study. Blood. 1995;86(2):666-76.
7. Carlotti E, Pettenella F, Amaru R, Slater S, Lister TA, Barbui T, et al. Molecular characterization of a new recombination of the SIL/TAL- 1 locus in a child with T-cell acute lymphoblastic leukemia. Br J Haematol. 2002;118(4):1011-8.
8. Stock W, Westbrook CA, Sher DA, Dodge R, Sobol RE, Wurster-Hill D, et al. Low incidence of TAL1 gene rearrangements in adult acute lymphoblastic leukemia: a cancer and leukemia group B study (8762). Clin Cancer Res. 1995;1(4):459-63.
9. Ballerini P, Landman Parker J, Cayuela JM, Asnafi V, Labopin M, Gandemer V, et al. Impact of genotype on survival of children with T cell acute lymphoblastic leukemia treated according to the French protocol FRALLE 93: the effect of TLX3/HOX11L2 gene expression on outcome. Haematologica. 2008;93(11):1658-65.
10. Mansur MB, Emerenciano M, Brewer L, Sant'Ana M, Mendonça N, Thuler LC, et al. SIL-TAL1 fusion gene negative impact in T cell acute lymphoblastic leukemia outcome. Leuk Lymphoma. 2009;(5088): 1318-25.
11. Bash RO, Crist WM, Shuster JJ, Link MP, Amylon M, Pullen J, et al. Clinical features and outcome of T cell acute lymphoblastic leukemia in childhood with respect to alterations at the TAL1 locus: a Pediatric Oncology Group study. Blood. 1993;81(8):2110-7.
12. Kikuchi A, Hayashi Y, Kobayashi S, Hanada R, Moriwaki K, Yamamoto K, et al. Clinical significance of TAL1 gene alteration in childhood T cell acute lymphoblastic leukemia and lymphoma. Leukemia. 1993;7(7):933-8.
13. Bene MC, Castoldi G, Knapp W, Ludwig WD, Matutes E, Orfao A, van’t Veer MB. Proposal for the immunological classification of acute leukemias. European Group for the Immunological Characterization of Leukemias (EGIL). Leukemia 1995;9(10):1783-6.
14. Schrappe M, Valsecchi MG, Bartram CR, Panzer-Grümayer R, Möricke A, et al. Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL: results of the AIEOP-BFMALL 2000 study. Blood. 2011;118(8):2077-84.
15. Pongers-Willemse MJ, Seriu T, Stolz F, d’Aniello E, Gameiro P, Pisa P, et al. Primers and protocols for standardized detection of minimal residual disease in acute lymphoblastic leukemia using immunoglobulin and T cell receptor gene rearrangements and TAL1 deletions as PCR target: report of the BIOMED-1 Concerted Action: investigation of minimal residual disease in acute leukemia. Leukemia. 1999;13(1): 110-8.